About Encompass Health Corporation
https://www.encompasshealth.comEncompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice.
CEO
Mark J. Tarr
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-07-01 | Forward | 1257:1000 |
| 2006-10-26 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 256
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
UBS
Buy
B of A Securities
Buy
Truist Securities
Buy
RBC Capital
Outperform
Barclays
Overweight
Keybanc
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:10.24M
Value:$1.03B
BLACKROCK, INC.
Shares:9.88M
Value:$989.7M
BLACKROCK INC.
Shares:9.05M
Value:$906.68M
Summary
Showing Top 3 of 725
About Encompass Health Corporation
https://www.encompasshealth.comEncompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.48B ▲ | $449.1M ▲ | $126.5M ▼ | 8.56% ▼ | $1.26 ▼ | $333.1M ▼ |
| Q2-2025 | $1.46B ▲ | $367.8M ▲ | $142.1M ▼ | 9.75% ▼ | $1.41 ▼ | $347.1M ▼ |
| Q1-2025 | $1.46B ▲ | $363.9M ▲ | $151.5M ▲ | 10.41% ▲ | $1.5 ▲ | $349.6M ▲ |
| Q4-2024 | $1.41B ▲ | $353.6M ▲ | $120.9M ▲ | 8.6% ▲ | $1.2 ▲ | $312.4M ▲ |
| Q3-2024 | $1.35B | $349.2M | $108.2M | 8.01% | $1.08 | $297.1M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $48.7M ▼ | $6.87B ▲ | $3.68B ▼ | $2.37B ▲ |
| Q2-2025 | $170.6M ▲ | $6.79B ▲ | $3.7B ▼ | $2.28B ▲ |
| Q1-2025 | $95.8M ▲ | $6.64B ▲ | $3.7B ▲ | $2.16B ▲ |
| Q4-2024 | $85.4M ▼ | $6.53B ▲ | $3.69B ▼ | $2.07B ▲ |
| Q3-2024 | $239.5M | $6.46B | $3.73B | $1.96B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $174.6M ▼ | $270.8M ▲ | $-201.3M ▼ | $-113.2M ▼ | $-43.7M ▼ | $83.7M ▼ |
| Q2-2025 | $184.9M ▼ | $270.2M ▼ | $-165.4M ▼ | $-90.2M ▲ | $14.6M ▲ | $113.3M ▼ |
| Q1-2025 | $196.5M ▲ | $288.6M ▲ | $-158.5M ▲ | $-130.4M ▲ | $-300K ▲ | $125.5M ▲ |
| Q4-2024 | $163.8M ▲ | $278.8M ▲ | $-203.7M ▼ | $-150.9M ▼ | $-75.8M ▼ | $80.1M ▼ |
| Q3-2024 | $147.8M | $267.8M | $-161.5M | $-89.5M | $16.8M | $120.3M |
Revenue by Products
| Product | Q3-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Inpatient | $0 ▲ | $0 ▲ | $0 ▲ | $1.42Bn ▲ |
 Managed Care | $150.00M ▲ | $160.00M ▲ | $160.00M ▲ | $0 ▼ |
 Medicaid | $50.00M ▲ | $50.00M ▲ | $50.00M ▲ | $0 ▼ |
 Medicare | $880.00M ▲ | $950.00M ▲ | $940.00M ▼ | $0 ▼ |
 Outpatient and Other | $0 ▲ | $0 ▲ | $0 ▲ | $40.00M ▲ |
 Patients | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Workers Compensation | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
CEO
Mark J. Tarr
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-07-01 | Forward | 1257:1000 |
| 2006-10-26 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 256
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
UBS
Buy
B of A Securities
Buy
Truist Securities
Buy
RBC Capital
Outperform
Barclays
Overweight
Keybanc
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:10.24M
Value:$1.03B
BLACKROCK, INC.
Shares:9.88M
Value:$989.7M
BLACKROCK INC.
Shares:9.05M
Value:$906.68M
Summary
Showing Top 3 of 725